Dementia news is almost relentlessly grim – a steady drumbeat of rising cases and elusive cures.More bad news came in 2025, when semaglutide, the blockbuster GLP-1 drug celebrated for treating diabetes, obesity and various other conditions, failed to slow Alzheimer’s progression. The setback prompted semaglutide’s developer, Novo Nordisk, to pull the plug on its high-profile dementia trial.Beyond the headlines, however, a quieter, more encouraging shift is under way. Significant strides in brain health research are helping us tailor treatment, refine diagnosis and manage risk far more effectively.
